Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17258152 | 1.00 | USP2 (0.40) | USP2TSHRPOLBHPGDL3MBTL1 | |
| SCHEMBL6327678 | 0.67 | KCNA5 (0.48) | USP2TSHRPOLBHPGDL3MBTL1 | |
| SCHEMBL8618900 | 0.67 | KCNA5 (0.48) | USP2TSHRPOLBHPGDL3MBTL1 | |
| SCHEMBL6327679 | 0.67 | KCNA5 (0.48) | USP2TSHRPOLBHPGDL3MBTL1 | |
| SCHEMBL13513362 | 0.66 | GRM4 (0.42) | USP2TSHRHPGDL3MBTL1HTT | |
| SCHEMBL1809334 | 0.64 | HPGD (0.53) | USP2TSHRPOLBHPGDL3MBTL1 | |
| SCHEMBL15956234 | 0.64 | L3MBTL1 (0.53) | USP2TSHRPOLBHPGDL3MBTL1 | |
| SCHEMBL17312874 | 0.64 | L3MBTL1 (0.53) | USP2TSHRPOLBHPGDL3MBTL1 | |
| SCHEMBL16621035 | 0.64 | HPGD (0.53) | USP2TSHRPOLBHPGDL3MBTL1 | |
| SCHEMBL11971363 | 0.64 | HPGD (0.53) | USP2TSHRPOLBHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | PIM1, PIM3, PIM2 | USP2 2879/4885TSHR 3792/4885POLB 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.